Dr Muhammad Ruhul Amin Shipa details
Location:
- University College Hospital
GMC/GDC number:
7485284
Professional background
Dr. Muhammad Shipa is an academic consultant rheumatologist and "lupologist" at University College London Hospitals (UCLH) and serves as a principal investigator at University College London (UCL). His work focuses on advancing autoimmune research, with a particular emphasis on personalised therapy, disease endotyping, and patient-centred translational science in autoimmune rheumatic diseases, particularly systemic lupus erythematosus (SLE) and other autoimmune connective tissue disorders. He integrates clinical expertise with advanced computational science to address the complexities of autoimmune diseases.
Dr. Shipa has received extensive training in prestigious and renowned hospitals across London and Singapore. Before joining UCLH, he served as a Connective Tissue Disease (CTD) consultant at Cambridge University Hospital. He currently holds an honorary clinician scientist position at the Wellcome Sanger Institute. His research on the pathogenesis and novel combination therapeutic approaches in SLE earned him a PhD from UCL. His pioneering work has led to the discovery of theranostic biomarkers that enhance the precision of B-cell-targeted therapies, contributing to advancements in personalised medicine. These achievements were recognised with the Junior Investigator Award from the American College of Physicians in 2021.
Beyond his clinical and research roles, Dr. Shipa is actively engaged with national and international rheumatology societies. Through his research, clinical work, and collaborative initiatives, he continues to make significant contributions to the field, shaping the future of autoimmune disease treatment and personalised medicine.
Specialties
Research interests
Systemic lupus Erythematosus (SLE)
Auto-immune rheumatic diseases
Sjogren’s disease
Languages spoken
Hindi, Bengali
Publications
1. Muhammad Shipa, Liliana Ribeiro Santos, Dao X Nguyen, Andrew Embleton-Thirsk, Mariea Parvaz, Lauren L Heptinstall, Ruth J Pepper, Prof. David A Isenberg, Prof. Caroline Gordon, and Prof. Michael R Ehrenstein. Identification of biomarkers to stratify response to B cell targeted therapies in a randomized trial for systemic lupus erythematosus. Manuscript accepted Lancet rheumatology.
2. Shipa, M; Yeoh, S-A. GCA- Prank or frank. (Review on GCA) – manuscript accepted to Mediterranean Journal of rheumatology.
3. Shipa MR, Heyer N, Mansoor R, Deakin CT, Madenidou AV, Bouraioui A, Fisher C, Leandro M, Ciurtin C, Sen D. Adalimumab or etanercept as first line biologic therapy in enthesitis related arthritis (ERA) - a drug-survival single center study spanning 10 years. Semin Arthritis Rheum. 2022; 28;55:152038.
4. Santos, L., Shipa, M., Lopes, J., & Ehrenstein, M. (2022). Beating B Cells in Lupus Nephritis. Portuguese Journal of Nephrology and Hypertension, 36 (3).
5. Shipa, M. R. A., Di Cicco, M., Balogh, E., et al. Drug-Survival Profiling of Second-Line Biologic Therapy in Rheumatoid Arthritis: Choice of Another TNFi or a Biologic of Different Mode of Action?. Modern Rheumatology,2022, roac086.
6. Shipa MRA, Langley L, Sacks B, Yeoh SA, Mainuddin MD, Mukerjee D, Castelino M, Ehrenstein MR. Increased erythrocyte mean corpuscular volume by methotrexate predicts clinical response in psoriatic arthritis. Rheumatology.2022;9:276.
7. Shipa M, Embleton-Thirsk A, Parvaz M, Santos LR, Muller P, Chowdhury K, Isenberg DA, Doré CJ, Gordon C, Ehrenstein MR; BEAT-LUPUS Investigators, D'Cruz DP, Jordan N, Parker B, Lightstone L, Salama A, Pyne D, Edwards CJ, Griffiths B, Vital EM, Rhodes B, Yee CS, Akil M, Topham P, Gullick NJ. Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus: A Randomized Controlled Trial. Ann Intern Med. 2021;174:1647-1657.
8. Muhammad RA Shipa, Raj Amarnani , Su-Ann Yeoh et. al. Early reduction in circulating monocyte count predicts maintenance of remission in rheumatoid arthritis patients treated with anti-TNF therapy – accepted for publication in Ann Rheum Dis. DOI - http://dx.doi.org/10.1136/annrheumdis-2021-220642
9. Shipa M, Yeoh S-A, Embleton-Thirsk A, Mukerjee D, Ehrenstein M. The synergistic efficacy of hydroxychloroquine with methotrexate is accompanied by increased erythrocyte mean corpuscular volume - Rheumatology, 2021; keab403.
10. McCann N, Amarnani R, Shipa M, et. al. Epstein-Barr virus associated haemophagocytic lymphohistiocytosis treated with anakinra and rituximab: A case report, Clinical Infection in Practice. 2021; 9: 100060.
11. Gupta R, Shipa M, Yeoh SA, et. al. An unfavorable outcome following switching intravenous abatacept and tocilizumab to subcutaneous forms during the COVID-19 pandemic. Rheumatology (Oxford). 2021;60(2):977-979.
12. Greenwood M, Shipa M, Yeoh SA, et. al. Methotrexate reduces withdrawal rates of TNF inhibitors due to ineffectiveness in rheumatoid arthritis but only in patients who are seropositive. Ann Rheum Dis. 2020;79 :1516-1517
13. Shipa M, Di Cicco M, Roussou E. CNS Vasculitis in Anti-Synthetase Syndrome. Mediterranean journal of rheumatology. 2020; 30; 220–223.
14. Iqbal M, Siddiqui M, Shipa M, et. al. Association Between Acute Stroke and Metabolic Syndrome. J Medicine. 2010; 11: 124-127.
15. Hossain A, Islam Q, Shipa M, et. al. An Unusual Cause of Seizure in Clinical Practice. JOM. 2011; 12, 177-179.
16. Al-Aziz M, Ahmed M, Shipa A, et. al. Choledochoduodenal fistula secondary to duodenal ulcer disease and choledocholithiasis. JAFMC; 2008; 4: 38-41.
CHAPTER IN BOOK:
1. Shipa M, Isenberg D. Pregnancy and myositis – Practical management of pregnant patient with rheumatology disease (Oxford University Press 2021).
ABSTRACT:
1. Shipa M, santos l, Nguyen D, et al. Belimumab After Rituximab Targets IgA2 Anti-dsDNA Antibody Production and Shifts Repopulating B-cells Towards an Anergic, Non-pathogenic Phenotype in Systemic Lupus Erythematosus. [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9).
2. Yeoh SA, Shipa M, Ehrenstein M. Highly differentiated CD4 and CD8 T effector memory cells re-expressing CD45RA (TEMRA) are associated with active disease refractory to anti-TNF therapy in rheumatoid arthritis – EULAR congress 2022.
3. Roussou E, Shipa M. Perceived reported disease activity during pregnancy obtained from women with rheumatological disease is at the same level as before pregnancy – Autoimmunity 2022.
4. Shipa. M, Ehrenstein MR. Belimumab after rituximab shifts repopulating B-cells towards an anergic, non-pathogenic phenotype in systemic lupus erythematosus - BSI congress.
5. Kimpton J, Shipa M, Hawkins E, et al. anti-citrullinated protein antibody positivity is associated with reduced withdrawal rates of abatacept in rheumatoid arthritis but only in patients who are anti-nuclear antibody (ANA) negative. Annals of the Rheumatic Diseases 2021; 80:1136.
6. Amarnani R, Mainuddin M, Shipa M, et al. reduction in monocyte count predicts sustained remission in rheumatoid arthritis patients treated with anti-TNF therapy. Annals of the Rheumatic Diseases 2021; 80:448-449.
7. Greenwood M, Shipa M, Ehrenstein M. Distinct effects of methotrexate in combination with adalimumab or etanercept according to CCP antibody status in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2020; 79:988.
8. Shipa M, Yeoh SA, Mukerjee D, Ehrenstein M. An increase in Red cell Mean Corpuscular Volume by Methotrexate is potentiated by Hydroxychloroquine and predicts clinical response in rheumatoid arthritis. Arthritis Rheumatol. 2020, 72 (suppl 10).
9. Meena Naja, Liliana R Santos, Muhammad Shipa, Greenwood Mandy, Madhura Castelino, P282 Outcome for PsA biologic switchers following primary inefficacy of TNFi therapy in a secondary care cohort: sequential TNFi versus switching mode of action, Rheumatology. 2020, 59 (suppl 2)
10. Shipa M, Madenidou A, Choida v, et. al. Predictors of response to TNFi – alpha in juvenile idiopathic arthritis: A single-center experience. Arthritis Rheumatol, 2019; 71 (suppl 10).
11. Shipa M, Di Cicco M, Balogh E et. al. Tailoring second-line biologic therapy in rheumatoid arthritis: new findings on the usefulness of antibody status to optimize drug selection, 2017; 69 (suppl 10).
12. Shipa M, Di Cicco M, Balogh E, et. al. Real-life data on comparison between second tumour necrosis factor inhibitor versus biologics with different mode of action after secondary failure of initial tumour necrosis factor in rheumatoid arthritis. Rheumatology. 2017; 56 (suppl_2).